RhumbLine Advisers’s Monopar Therapeutics MNPR Stock Holding History

RhumbLine Advisers’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$446K	Sell	5,600 -30	-0.5%	-$3.22K	﹤0.01%	2803
2026 Q2	$521K	Buy	5,630 +684	+14%	+$42.3K	﹤0.01%	2739
2026 Q1	$271K	Sell	4,946 -44	-0.9%	-$2.66K	﹤0.01%	2960
2025 Q4	$326K	Sell	4,990 -298	-6%	-$24.3K	﹤0.01%	2922
2025 Q3	$432K	Sell	5,288 -562	-10%	-$25.1K	﹤0.01%	2790
2025 Q2	$209K	Buy	+5,850	New	+$212K	﹤0.01%	3205

Other funds holding MNPR

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

RhumbLine Advisers's MNPR Position: Q3 2026 in Review

RhumbLine Advisers reduced its Monopar Therapeutics (MNPR) stake by 0.53% in Q3 2026, selling an estimated $3.22K and leaving 5,600 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

RhumbLine Advisers first reported a position in MNPR in Q2 2025 and has held it in 6 quarters since. The position peaked at $521K in Q2 2026. 43 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

RhumbLine Advisers held 5,600 shares of Monopar Therapeutics worth $446K as of Q3 2026.
RhumbLine Advisers sold 30 Monopar Therapeutics shares in Q3 2026, an estimated $3.22K.
Monopar Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2803 holding.
RhumbLine Advisers first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 6 quarters since.
RhumbLine Advisers's Monopar Therapeutics position peaked at $521K in Q2 2026.
43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.